FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005709546> ?p ?o ?g. }

• W2005709546 endingPage "1914" @default.
• W2005709546 startingPage "1902" @default.
• W2005709546 abstract "The safety, efficacy, and pharmacokinetics of monthly subcutaneous injections of a new leuprolide acetate (LA) depot formulation were investigated in patients with advanced prostate cancer.The 2-part, 6-month (168-day), open-label, multicenter study enrolled male patients diagnosed with adenocarcinoma of the prostate (Jewett stage C or D). LA-2500 7.5-mg (a new subcutaneous depot formulation containing 7.5 mg of LA) injections were administered at monthly (28-day) intervals. The primary efficacy parameter was total serum testosterone level. A breakthrough response was defined as a single testosterone measurement > 50 ng/dL after achieving castration testosterone levels. Testosterone was isolated from sera by alumina column chromatography and measured by radioimmunoassay (RIA). LA was purified by solid-phase extraction and high-performance liquid chromatography and was then quantitated by RIA.One hundred seventeen of the 120 enrolled patients completed the 6-month study. Three patients withdrew for reasons not related to treatment. LA had a mean (SD) maximal concentration of 26.3 (12.6) ng/mL at 4.66 (1.44) hours and was detected for a mean of 37 days (range, 28-49 days). By day 28, 94.1% (112/119) of the patients achieved medical castration (serum testosterone < or = 50 ng/dL). By day 42, 100.0% (118/118) of the patients remaining in the study had serum testosterone levels < or = 50 ng/dL and 97.5% (115/118) had levels < or = 20 ng/dL. At study completion, the mean (SD) serum testosterone level was 6.12 (4.3) ng/dL (range, 3.0-27.0 ng/dL). No breakthrough or acute-on-chronic responses were reported throughout the study. From baseline to month 6, mean (SD) luteinizing hormone level decreased from 8.0 (7.3) mIU/mL to 0.09(0.1) mIU/mL, and mean (SD) prostate-specific antigen level decreased from 32.9 (86.3) ng/mL to 3.2 (12.0) ng/mL. Treatment-related adverse events were reported by 74.2% (89/120) of patients, the most common being hot flashes (56.7%).This 6-month, open-label, noncontrolled study showed LA-2500 7.5-mg depot was well tolerated and maintained testosterone suppression (< or = 50 ng/dL) in the patients completing the study without any testosterone breakthrough responses." @default.
• W2005709546 created "2016-06-24" @default.
• W2005709546 creator A5003454382 @default.
• W2005709546 creator A5003471767 @default.
• W2005709546 creator A5019406303 @default.
• W2005709546 creator A5037912753 @default.
• W2005709546 creator A5053457391 @default.
• W2005709546 creator A5079963586 @default.
• W2005709546 date "2002-11-01" @default.
• W2005709546 modified "2023-10-14" @default.
• W2005709546 title "A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer" @default.
• W2005709546 cites W1993709219 @default.
• W2005709546 cites W1996285570 @default.
• W2005709546 cites W2001536930 @default.
• W2005709546 cites W2017711158 @default.
• W2005709546 cites W2026878657 @default.
• W2005709546 cites W2040196584 @default.
• W2005709546 cites W2055051372 @default.
• W2005709546 cites W2070356092 @default.
• W2005709546 cites W2086413985 @default.
• W2005709546 cites W2102333999 @default.
• W2005709546 cites W2138178697 @default.
• W2005709546 cites W2522707256 @default.
• W2005709546 cites W28682465 @default.
• W2005709546 doi "https://doi.org/10.1016/s0149-2918(02)80087-x" @default.
• W2005709546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12501882" @default.
• W2005709546 hasPublicationYear "2002" @default.
• W2005709546 type Work @default.
• W2005709546 sameAs 2005709546 @default.
• W2005709546 citedByCount "75" @default.
• W2005709546 countsByYear W20057095462012 @default.
• W2005709546 countsByYear W20057095462013 @default.
• W2005709546 countsByYear W20057095462014 @default.
• W2005709546 countsByYear W20057095462015 @default.
• W2005709546 countsByYear W20057095462016 @default.
• W2005709546 countsByYear W20057095462017 @default.
• W2005709546 countsByYear W20057095462018 @default.
• W2005709546 countsByYear W20057095462019 @default.
• W2005709546 countsByYear W20057095462020 @default.
• W2005709546 countsByYear W20057095462021 @default.
• W2005709546 countsByYear W20057095462022 @default.
• W2005709546 countsByYear W20057095462023 @default.
• W2005709546 crossrefType "journal-article" @default.
• W2005709546 hasAuthorship W2005709546A5003454382 @default.
• W2005709546 hasAuthorship W2005709546A5003471767 @default.
• W2005709546 hasAuthorship W2005709546A5019406303 @default.
• W2005709546 hasAuthorship W2005709546A5037912753 @default.
• W2005709546 hasAuthorship W2005709546A5053457391 @default.
• W2005709546 hasAuthorship W2005709546A5079963586 @default.
• W2005709546 hasConcept C112705442 @default.
• W2005709546 hasConcept C121608353 @default.
• W2005709546 hasConcept C126322002 @default.
• W2005709546 hasConcept C126894567 @default.
• W2005709546 hasConcept C134018914 @default.
• W2005709546 hasConcept C176685330 @default.
• W2005709546 hasConcept C2776235491 @default.
• W2005709546 hasConcept C2779256933 @default.
• W2005709546 hasConcept C2779279991 @default.
• W2005709546 hasConcept C2780192828 @default.
• W2005709546 hasConcept C71315377 @default.
• W2005709546 hasConcept C71924100 @default.
• W2005709546 hasConceptScore W2005709546C112705442 @default.
• W2005709546 hasConceptScore W2005709546C121608353 @default.
• W2005709546 hasConceptScore W2005709546C126322002 @default.
• W2005709546 hasConceptScore W2005709546C126894567 @default.
• W2005709546 hasConceptScore W2005709546C134018914 @default.
• W2005709546 hasConceptScore W2005709546C176685330 @default.
• W2005709546 hasConceptScore W2005709546C2776235491 @default.
• W2005709546 hasConceptScore W2005709546C2779256933 @default.
• W2005709546 hasConceptScore W2005709546C2779279991 @default.
• W2005709546 hasConceptScore W2005709546C2780192828 @default.
• W2005709546 hasConceptScore W2005709546C71315377 @default.
• W2005709546 hasConceptScore W2005709546C71924100 @default.
• W2005709546 hasIssue "11" @default.
• W2005709546 hasLocation W20057095461 @default.
• W2005709546 hasLocation W20057095462 @default.
• W2005709546 hasOpenAccess W2005709546 @default.
• W2005709546 hasPrimaryLocation W20057095461 @default.
• W2005709546 hasRelatedWork W1978459015 @default.
• W2005709546 hasRelatedWork W1985557198 @default.
• W2005709546 hasRelatedWork W2055103711 @default.
• W2005709546 hasRelatedWork W2157439642 @default.
• W2005709546 hasRelatedWork W2381910020 @default.
• W2005709546 hasRelatedWork W2404899404 @default.
• W2005709546 hasRelatedWork W2409692580 @default.
• W2005709546 hasRelatedWork W2883402525 @default.
• W2005709546 hasRelatedWork W2944924574 @default.
• W2005709546 hasRelatedWork W2993729724 @default.
• W2005709546 hasVolume "24" @default.
• W2005709546 isParatext "false" @default.
• W2005709546 isRetracted "false" @default.
• W2005709546 magId "2005709546" @default.
• W2005709546 workType "article" @default.